InnerMedical

About InnerMedical

InnerMedical Co., Ltd. operates as a provider of interventional diagnostic and treatment solutions, with a strategic focus on gastroenterology, pulmonology, and cardiology. Established in 2015 by Xiaosong Bai and headquartered in Shenzhen, China, the company directs its efforts towards addressing critical diseases through the development of medical devices. The firm has achieved significant funding milestones, securing $15.4 million over four rounds, with the latest being a Series D round in December 2022. This financial backing comes from a consortium of 17 institutional investors, including notable firms like Green Pine Capital Partners and Sangel Capital.

The company's business model is centered on the manufacturing and sale of specialized medical equipment. A key achievement for InnerMedical was being the first in China to independently develop and produce a Mini-Probe Endoscopic Ultrasound (EUS) system. This system is designed to generate high-definition ultrasonic images for the early detection of cancers in the digestive and respiratory systems. The product portfolio extends to HD digital endoscopes, ultrasound probes, and an intravascular ultrasound system. In a significant step for its international market presence, the company's Miniprobe ultrasound system has received CE MDR certification, ensuring it meets European market standards.

InnerMedical dedicates a substantial portion of its resources to research and development, reinvesting over 30% of its revenue into this area. The company has established multiple technical platforms in fields such as ultrasound electronics, optical technology, and interventional devices, managed by a team of over 200 R&D experts out of more than 400 total employees. Its manufacturing and R&D facilities comply with Good Manufacturing Practice (GMP) and ISO 13485 requirements, indicating a commitment to a standardized quality assurance system. This focus on development has resulted in a portfolio of over 10 patents and multiple software copyrights.